BC
TGTX icon

Brookfield Corp’s TG Therapeutics TGTX Stock Holding History

Brookfield Corp’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-123,193
Closed -$3.06M – 488
2023
Q2 		$3.06M Sell
123,193
-375,098
-75% -$9.69M 0.01% 361
2023
Q1 		$7.49M Buy
498,291
+242,842
+95% +$3.69M 0.03% 226
2022
Q4 		$3.02M Sell
255,449
-42,394
-14% -$308K 0.01% 340
2022
Q3 		$1.76M Buy
297,843
+67,153
+29% +$440K 0.01% 476
2022
Q2 		$980K Buy
230,690
+46,897
+26% +$293K ﹤0.01% 506
2022
Q1 		$1.75M Buy
183,793
+115,484
+169% +$1.34M 0.01% 418
2021
Q4 		$1.3M Buy
68,309
+40,980
+150% +$1.06M 0.01% 400
2021
Q3 		$910K Buy
27,329
+8,880
+48% +$275K ﹤0.01% 433
2021
Q2 		$716K Buy
+18,449
New +$724K ﹤0.01% 492

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Brookfield Corp's TGTX Position: Q3 2023 in Review

Brookfield Corp sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 123,193 shares — an estimated $3.06M sold.

Brookfield Corp first reported a position in TGTX in Q2 2021 and held it in 9 quarters. The position peaked at $7.49M in Q1 2023. 235 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Brookfield Corp reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 123,193 TG Therapeutics shares in Q3 2023, an estimated $3.06M.
  • Brookfield Corp first reported a position in TG Therapeutics in Q2 2021 and held it in 9 quarters.
  • Brookfield Corp's TG Therapeutics position peaked at $7.49M in Q1 2023.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.